Assessing Selected Aspects of Adequacy of the Growth Hormone-Somatomedin Axis in Short Children with Quantitatively Normal Growth Hormone Secretion

  • D. P. Dempsher
  • S. E. Tollefsen
  • E. Heath-Monnig
  • B. Trivedi
  • J. R. GavinIII
  • W. H. Daughaday
  • D. M. Bier
Part of the Serono Symposia, USA book series (SERONOSYMP)


Conventional approaches for confirming growth hormone adequacy in children with growth failure are the subject of considerable current debate. There is general agreement that individuals who fail repeatedly to secrete growth hormone in response to pharmacological provocation are growth hormone deficient. However, there is no uniform opinion concerning the diagnosis of, or even the presence of, lesser degrees of growth hormone insufficiency including those which might result from structurally abnormal molecules, defects at the growth hormone receptor/postreceptor levels, ineffective mutant somatomedins, or defective IGF-1 receptor/postreceptor signal transduction at the cellular level.


Growth Hormone Growth Hormone Deficiency Human Growth Hormone Growth Hormone Receptor Short Child 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gavin JR III, Trivedi B, Daughaday WH. Homologous IM-9 lymphocyte radioreceptor and recepfor modulation assays for human serum growth hormone. J Clin Endocrinol Metab 1982; 55: 133–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Ymer SI, Herington AC. Evidence for the specific binding of growth hormone to a receptor-like protein in rabbit serum. Mol Cell Endocrinol 1985; 41: 153–61.PubMedCrossRefGoogle Scholar
  3. 3.
    Herington AC, Ymer S, Roupas P, Stevenson J. Growth hormone-binding proteins in high-speed cytosols of multiple tissues of the rabbit. Biochim Biophys Acta 1986; 881: 236–40.PubMedCrossRefGoogle Scholar
  4. 4.
    Herington AC, Ymer S, Stevenson J. Identification and characterization of specific binding proteins for growth hormone in normal human sera. J Clin Invest 1986; 77: 1817–23.PubMedCrossRefGoogle Scholar
  5. 5.
    Baumann G, Stolar MW, Amburn K, Barsano CP, DeVries BC. A specific growth hormone-binding protein in human plasma: initial characterization. J Clin Endocrinol Metab 1986; 62: 134–41.PubMedCrossRefGoogle Scholar
  6. 6.
    Spencer SA, Hammonds RG, Waters MJ, Wood WI. Purification and characterization of a growth hormone receptor from rabbit liver and a related binding protein from rabbit serum. In: International symposium on growth hormone: basic and clinical aspects. Tampa, June 14–18, 1987: 50.Google Scholar
  7. 7.
    Daughaday WH, Trivedi B. Absence of serum growth hormone binding protein in patients with growth hormone receptor deficiency (Laron dwarfism). Proc Natl Acad Sci USA 1987; 84: 4636–40.PubMedCrossRefGoogle Scholar
  8. 8.
    Baumann G, Shaw MA, Winter RJ. Absence of the plasma growth hormone-binding protein in Laron-type dwarfism. J Clin Endocrinol Metab 1987; 65: 814–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Carmina E, LoCoco R, Porcelli P, Lanzara P, Janni A. Dwarfism with high somatomedin activity and delayed bone age: a syndrome of receptor insensitivity to the somatomedins? In: LaCauza C, Root AW, eds. Problems in pediatric endocrinology. New York: Academic Press, 1980: 147–72.Google Scholar
  10. 10.
    Lanes R, Plotnick LP, Spencer EM, Daughaday WH, Kowarski AA. Dwarfism associated with normal serum growth hormone and increased bioassayable, receptorassayable and immunoassayable somatomedin. J Clin Endocrinol Metab 1980; 50: 485–90.PubMedCrossRefGoogle Scholar
  11. 11.
    Bierich JR, Moeller H, Ranke MB, Rosenfeld RG. Pseudopituitary dwarfism due to resistance to somatomedin: a new syndrome. Eur J Pediatr 1984; 142: 186–91.PubMedCrossRefGoogle Scholar
  12. 12.
    Kaplowitz PB, D’Ercole AJ, Underwood LE, Van Wyk JJ. Stimulation by somatomedin-C of aminoisobutyric acid uptake in human fibroblasts: a possible test for cellular responsiveness to somatomedin. J Clin Endocrinol Metab 1984; 58: 176–81.PubMedCrossRefGoogle Scholar
  13. 13.
    Heath-Monnig E, Wohltmann HJ, Mills-Dunlap B, Daughaday WH. Measurement of insulin-like growth factor I (IGF-I) responsiveness of fibroblasts of children with short stature: identification of a patient with IGF-I resistance. J Clin Endocrinol Metab 1987; 64: 501–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Conover CA, Hintz RL, Rosenfeld RG. Impaired synergism between somatomedin C/insulin-like growth factor I and dexamethasone in the growth of fibroblasts from a patient with insulin resistance. Pediatr Res 1987; 22: 188–91.PubMedCrossRefGoogle Scholar
  15. 15.
    Ikkos D, Luft R, Gemzell CA. The effect of human growth hormone in man. Lancet 1958; 1: 720–1.PubMedCrossRefGoogle Scholar
  16. 16.
    Medical Research Council. The effectiveness in man of human growth hormone. Lancet 1959; 1: 7–12.Google Scholar
  17. 17.
    Henneman PH, Forbes AP, Moldawer M, Dempsey EF, Carroll EL. Effects of human growth hormone in man. J Clin Invest 1960; 39: 1223–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Shepard TH II, Nielsen RL, Johnson ML, Bernstein N. Human growth hormone. I. Metabolic balances studies carried out in a hypopituitary child. Am J Dis Child 1960; 99: 90–6.Google Scholar
  19. 19.
    Prader A, Illig R, Szeky J, Wagner H. The effect of human growth hormone in hypopituitary dwarfism. Arch Dis Child 1964; 39: 535–44.PubMedCrossRefGoogle Scholar
  20. 20.
    Hubble D. Studies with human growth hormone. Arch Dis Child 1966; 41: 17–24.PubMedCrossRefGoogle Scholar
  21. 21.
    Brown GA, Stimmler L, Lines JG. Growth hormone-induced nitrogen retention in children of short stature. Arch Dis Child 1976; 42: 239–44.CrossRefGoogle Scholar
  22. 22.
    Prader A, Zachmann M, Poley JR, Illig R. The metabolic effect of a small uniform dose of human growth hormone in hypopituitary dwarfs and in control children. Acta Endocrinol (Copenh) 1968; 57: 115–28.Google Scholar
  23. 23.
    Clayton BE, Tanner JM, Vince FP. Diagnostic and prognostic value of short-term metabolic response to human growth hormone in short stature. Arch Dis Child 1971; 46: 405–13.PubMedCrossRefGoogle Scholar
  24. 24.
    Rudman D, Chyatte SB, Patterson JH, et al. Observations on the responsiveness of human subjects to human growth hormone. J Clin Invest 1971; 50: 1941–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Grunt JA, Enriquez AR. Acute and long-term responsiveness to growth hormone in children with short stature. Pediatr Res 1972; 6: 664–74.PubMedCrossRefGoogle Scholar
  26. 26.
    August GP, Hung W, Houck JC. The effects of growth hormone therapy on collagen metabolism in children. J Clin Endocrinol Metab 1974; 39: 1103–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Joss EE. Growth hormone deficiency in childhood. In: Falkner F, Kretchmer N, Rossi E, eds. Monographs in paediatrics; vol 5. Basel: S Karger, 1975: 1–83.Google Scholar
  28. 28.
    Lippe BM, Kaplan SA, Golden MP, Hendricks SA, Scott ML. Carbohydrate tolerance and insulin receptor binding in children with hypopituitarism: responses after acute and chronic human growth hormone administration. J Clin Endocrinol Metab 1981; 53: 507–13.PubMedCrossRefGoogle Scholar
  29. 29.
    Tamborlane WV, Genel M, Gianfredi S, Gertner JM. The effect of small but sustained elevations in circulating growth hormone on fuel metabolism in growth hormone deficiency. Pediatr Res 1984; 18: 212–5.PubMedCrossRefGoogle Scholar
  30. 30.
    Gertner JM, Tamborlane WV, Hintz RL, Horst RL, Genel M. The effects on mineral metabolism of overnight growth hormone infusion in growth hormone deficiency. J Clin Endocrinol Metab 1981; 53: 818–22.PubMedCrossRefGoogle Scholar
  31. 31.
    Ballard FJ, Burgoyne JL, Tomas FM, Penfold JL. Growth hormone-induced changes in myofibrillar protein breakdown in hypopituitary children. Clin Sci 1983; 64: 315–20.PubMedGoogle Scholar
  32. 32.
    Rudman D, Kutner MH, Fleming GA, et al. Effect of 10-day courses of human growth hormone on height of short children. J Clin Endocrinol Metab 1978; 46: 28–35.PubMedCrossRefGoogle Scholar
  33. 33.
    Rudman D, Kutner MH, Blackston RD, Jansen RD, Patterson JH. Normal variant short stature: subclassification based on responses to exogenous human growth hormone. J Clin Endocrinol Metab 1979; 49: 92–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Rudman D, Kutner MH, Goldsmith MA, Blackston RD. Predicting the response of growth hormone-deficient children to long term treatment with human growth hormone. J Clin Endocrinol Metab 1979; 48: 472–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Rudman D, Kutner MH, Goldsmith MA, Kenny J, Jennings H, Bain RP. Further observations on four subgroups of normal variant short stature. J Clin Endocrinol Metab 1980; 51: 1378–84.PubMedCrossRefGoogle Scholar
  36. 36.
    Rudman D, Kutner MH, Blackston RD. Children with normal-variant short stature: treatment with human growth hormone for six months. N Engl J Med 1981; 305: 123–31.PubMedCrossRefGoogle Scholar
  37. 37.
    Richter I, Heine W, Plath C, Mix M, Wutzke KD, Towe J. N tracer techniques for the differential diagnosis of dwarfism and prediction of growth hormone action in children. J Clin Endocrinol Metab 1987; 65: 74–7.Google Scholar

Copyright information

© Plenum Press, New York 1988

Authors and Affiliations

  • D. P. Dempsher
    • 1
  • S. E. Tollefsen
    • 1
  • E. Heath-Monnig
    • 1
  • B. Trivedi
    • 1
  • J. R. GavinIII
    • 1
  • W. H. Daughaday
    • 1
  • D. M. Bier
    • 1
  1. 1.School of MedicineWashington UniversitySt. LouisUSA

Personalised recommendations